GlassScriptPhysician profile
Nicholas J Delgado
NPI 1316053358
$1,410.00
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $329 · 2020: $377 · 2021: $501 · 2022: $203.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $370.33 | 2019-2021 | |
| Abbvie INC. | $239.87 | 2019-2022 | |
| Lilly USA, LLC | $162.57 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.17 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $96.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $68.47 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.09 | 2019 | |
| Allergan, INC. | $44.92 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $43.79 | 2021 | |
| Amgen INC. | $41.67 | 2019-2021 | |
| Esperion Therapeutics, INC. | $36.85 | 2021 | |
| Amarin Pharma, INC. | $36.10 | 2020-2021 | |
| Astellas Pharma US INC | $35.04 | 2019 | |
| Merck Sharp & Dohme LLC | $30.30 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.62 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $13.78 | 2019 | |
| Pfizer INC. | $12.43 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Delgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.